Effect of Pyridorin in Patients With Diabetic Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00320060
Recruitment Status : Completed
First Posted : April 27, 2006
Last Update Posted : April 27, 2006
Information provided by:

Brief Summary:
The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.

Condition or disease Intervention/treatment Phase
Diabetic Nephropathy Drug: Pyridorin (pyridoxamine dihydrochloride) Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 128 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes
Study Start Date : October 2001
Study Completion Date : January 2003

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and Females (non-pregnant and non-lactating) between 18 and 70 years of age with type 1 or type 2 diabetes
  • Sitting blood pressure of <=170/100 mm Hg at weeks -2 and -1
  • Hemoglobin A1C <=12% at week -2
  • Patients with diagnosis of diabetic nephropathy as defined by

    1. Serum Creatinine <=2.0 mg/dL at weeks -2 and -1
    2. Urinary albumin excretion >=300 mg/24 hours at week -2
    3. Diagnosis of diabetic retinopathy
  • Creatinine clearance >=40 mL/min at weeks -2 and -1
  • Voluntary written consent to participate in this study

Exclusion Criteria:

  • History of allergic or adverse response to any B vitamin
  • History of major cardiovascular or cerebrovascular events
  • History of cancer except adequately treated basal or squamous cell carcinoma of the skin
  • History of diabetic ketoacidosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00320060

Sponsors and Collaborators
Study Director: Thorsten P Degenhardt, Ph.D. BioStratum, Inc. Identifier: NCT00320060     History of Changes
Other Study ID Numbers: PYR-206
First Posted: April 27, 2006    Key Record Dates
Last Update Posted: April 27, 2006
Last Verified: April 2006

Keywords provided by BioStratum:
Diabetic nephropathy
Advanced Glycation Endproduct Inhibitor

Additional relevant MeSH terms:
Kidney Diseases
Diabetic Nephropathies
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs